DF NEW ENGLAND - 9

Checklist for Ocrevus / Ocrevus Zunovo (ocrelizumab) Referral

Patient	Name:	DOB: Dote:							
Referring Physician: NPI: NPI:									
Office Contact/Title/Email:									
Office Address:									
Office	Phone:	Office Fax:							
Best co	ntact n	umber for physician in case of reaction:							
Please return completed checklist and checklist items to initiate referral. Use this form as fax cover sheet.									
	Patien	ient demographic information							
	Insura	irance information and copy of insurance card/s (front and back). *Include primary and secondary insurance							
	Suppo	pporting clinical notes and office visits. Two notes preferred.							
	 Note should include any therapies tried/failed, and must include discussion about Ocrevus 								
	0	Medication list and allergies Last Ocrevus infusion note, if available							
	0								
	Supporting lab reports/orders for Ocrevus treatment Receive a set of the second sec								
	0	Baseline: CBC w diff, CMP, serum immunoglobulins, Hepatitis B screening, and brain MRI within 1 year							
	0	For continued therapy: CBC w diff and CMP prior to each infusion							
	0	Ensure all vaccinations are up to date prior to treatment. Live vaccines should be given at least 4 weeks							
		prior to treatment, and non-live vaccines should be given at least 2 weeks prior to treatment.							
	Ocrevu	us Prescribing Order (see attached)							
		We will obtain prior authorization and schedule your patient as soon as possible –							

Fax all information to our Infusion Coordinator: 508-698-8671 Call with any questions: 781-551-5812 option 4

Visit our website: www.InfusionCenterNE.com Email: info@infusioncenterne.com

> **Infusion Center of New England** 9 Payson Road, Suite 100, Foxboro MA 02035 Ph: 781-551-5812 Fax: 508-698-8671



Prescribing Order: Ocrevus / Ocrevus Zunovo (ocrelizumab)

Da	te of Order:		New S	start		Maintenance Date of last infusion: _				
Pat	tient Name:			DOB:			M/F:			
Diagnosis (include ICD-10 code/s):										
	NKDA	Allergies:								
Pat	tient Weight									
Pre	emedication	:								
	Acetamino	phen 1000mg PO		Diph	enhy	dramine 25mg IV				
	Loratadine	10mg or Cetirizine 10mg PO		Solu	med	lrol 125mg IV in 50ml ov	ver 15min			
	Diphenhyd	ramine 25mg PO		Othe	er:					
Lak	o Orders:									
		CMP every weeks		Oth	er:					
<u>Oc</u>	revus Medic	ation Order:								
Ocrevus 300mg IV on Day 1 and Day 15. Begin infusion at 30ml/hr and increase by 30ml/hr every 30min to a maxim										
	of 180ml/hr.									
	Ocrevus 600mg IV once every 6 months. Begin infusion at 40ml/hr then increase rate by 40ml/hr every 30 minutes to a maximum rate of 200ml/hr until completion.									
	Shorter Infusion Time: Ocrevus 600mg IV once every 6 months. Begin infusion at 100ml/hr for the first 15 min, increase to 200ml/hr for the next 15 min, increase to 250ml/hr for the next 30 min, then increase to 300ml/hr for the remaining 60 min.									
	Ocrevus Zunovo 920mg/23ml SC every 6 months. Infuse subcutaneously in the abdomen over approximately 10 minutes.									
✓	Post infusion observation: Required for 1 hour after all Ocrevus IV treatments and first Ocrevus Zunovo SC treatment									

□ NS 100ml/hr x 1 hour

Administration:

- ✓ Vital Signs: Pre-treatment, at every rate change, and post-treatment
- ✓ Do not administer if patient has signs or symptoms of active infection
- ✓ In case of infusion reaction, STOP infusion and follow ICNE infusion reaction protocol. Notify physician.

Ordering Provider Name

NPI

Signature

Date

Infusion Center of New England 9 Payson Road, Suite 100, Foxboro MA 02035 Ph: 781-551-5812 Fax: 508-698-8671